Eli Lilly has reported a decline in it third quarter earnings despite a 9% sales increase attributed to its Cymbalta and Alimta medications.

Earnings fell 5%, with net income falling to $1.24bn, as higher administrative expenses and a mandatory pharmaceutical manufacturer fee of $45m related to the US healthcare reforms took their toll.

The strong performance of Cymbalta and Alimta, particularly overseas, boosted Lilly’s performance. Cymbalta reported a 29% increase to $1.07bn, while Alimta grew 12% to approximately $629m.

Lilly’s best-selling drug, however, continues to be the antipsychotic Zyprexa, which reported turnover of $1.19bn representative of a 3% decline.

Zyprexa has recently lost patent exclusivity in Europe, while patent protection has expired in the US. Lilly has admitted that predicting the impact of generic competition on sales of the drug is difficult.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.